PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS) Files An 8-K Results of Operations and Financial ConditionItem 9.01Results of Operations and Financial Condition.
OnNovember 29, 2018, PhaseBio Pharmaceuticals, Inc. (the “Company”) reported financial results for the quarter endedSeptember30, 2018. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.
The information in this Item 9.01 of this Current Report on Form8-K (including Exhibit99.1) is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01Other Events.
On November 27, 2018, the Company issued a press release to announce that the Company has dosed the first patient in its Phase 2b clinical trial of PB1046 in pulmonary arterial hypertension. A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
PhaseBio Pharmaceuticals Inc ExhibitEX-99.1 2 phas-ex991_6.htm EX-99.1 phas-ex991_6.htm Exhibit 99.1 PhaseBio Reports Third Quarter 2018 Financial and Business Results Closed initial public offering that raised $43.0 million in net proceeds Demonstrated proof of concept for PB2452,…To view the full exhibit click here
